Focus and Innovation

The commercial success of our approved products allows us to continue to invest in our R&D pipeline, which is crucial for the future success of our company.

Basilea at a glance

Basilea is a revenue-generating, commercial-stage Swiss biotech company. Our activities are focused in the areas of oncology, hospital antibiotics and hospital antifungals. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and three oncology drug candidates in development. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 as a spin-out from Roche and is headquartered in the heart of the life sciences hub of Basel. The Basilea group currently has 225 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.

Vision and mission

People are at the heart of everything we do. We strive towards making a difference to patients. With expertise, care and persistence. We aim to be a leading provider of innovative medicines. For the benefit of patients.

Organization

Board of Directors

 

Domenico Scala, Chairman of the Board of Directors | Nationality: Swiss and Italian | Year of Birth: 1965.

Domenico Scala has been a member of the Board of Directors since 2011 and has been serving as the Chairman of the Board of Directors since 2016. He is also Chairman of the Audit Committee.

Mr. Scala served as chairman of the audit and compliance committee of FIFA (Fédération Internationale de Football Association) from 2012 to 2016. From 2007 to 2011, Mr. Scala was president and CEO of Nobel Biocare Holding AG and from 2003 to 2007, he was CFO of Syngenta International AG. Prior to that, he held various senior leadership positions at Roche Holding AG and was finance director with Panalpina Italy Spa and senior auditor with Nestlé SA.

Mr. Scala is chairman of the board of Oettinger Davidoff AG and a member of the board of Implantica MediSwiss AG. He is a member of the bank council of the Basler Kantonalbank, president of BaselArea, and chairman of the board of BAK Basel Economics AG.

Mr. Scala graduated with a master in economics from the University of Basel and holds executive development degrees from INSEAD and London Business School.

Thomas Werner, Ph.D., Vice Chairman of the Board of Directors | Nationality: German | Year of Birth: 1956

Thomas Werner, Ph.D., has been a member of the Board of Directors since 2011 and has been serving as the Vice Chairman of the Board of Directors since 2018. He is also Chairman of the Corporate Governance Committee and a member of the Compensation Committee.

Mr. Werner served as senior vice president & managing director of GlaxoSmithKline Germany from 2001 to 2008. From 1997 to 2000, he was managing director for Glaxo Wellcome Germany and director of the Central European Region. He also led Bristol-Myers Squibb Germany and Convatec Germany/Central Europe.

Mr. Werner is chairman of the board of Fertin Pharma and a member of the board of Vectura Group plc. He also serves as the chairman of the investment advisory committee of the Health for Life Capital Fund of Seventure Partners.

Mr. Werner graduated with a doctorate in chemistry from the University of Göttingen, Germany.

Martin Nicklasson, Ph.D., Member of the Board of Directors | Nationality: Swedish | Year of Birth: 1955

Martin Nicklasson, Ph.D., has been a member of the Board of Directors since 2013. He is also Chairman of the Compensation Committee and a member of the Audit Committee.

Mr. Nicklasson served as president and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB from 2007 to 2010. From 1999 to 2007 he held various executive vice president positions and was a member of the executive committee of AstraZeneca Plc.

Mr. Nicklasson is chairman of the board of Kymab Group Ltd., of Orexo AB and of Zealand Pharma A/S. He also serves as consultant at Excore Consulting KB.

Mr. Nicklasson is a certified pharmacist and holds a doctorate in Pharmaceutical Technology from the University of Uppsala. He is an honorary Associate Professor at the Pharmaceutical Faculty of the University of Uppsala.

Nicole Onetto, M.D., Member of the Board of Directors | Nationality: Canadian and French | Year of Birth: 1953

Nicole Onetto, M.D., has been a member of the Board of Directors since 2017. She is also a member of the Corporate Governance Committee.

Ms. Onetto is an independent consultant in oncology, drug development and translational research. She was deputy director & chief scientific officer at the Ontario Institute for Cancer Research from 2009 to 2016. From 2005 to 2009 she was senior vice president and chief medical officer at ZymoGenetics Inc. From 2002 to 2005, she served at OSI Pharmaceuticals, Inc., first as executive vice president Oncology, and then as chief medical officer and executive vice president. Her career in the pharmaceutical industry also includes senior management positions at Bristol-Myers Squibb and Nexstar Pharmaceuticals, which was acquired by Gilead Sciences, Inc.

Ms. Onetto is a member of the board of Sierra Oncology, Inc. and of NBE Therapeutics AG. Previously she served for eleven years as a board member of ImmunoGen Inc.

Ms. Onetto holds a doctor of medicine from the University of Paris and a master of pharmacology from the University of Montréal.

Ronald Scott, Member of the Board of Directors | Nationality: Swiss | Year of Birth: 1955

Ronald Scott has been a member of the Board of Directors since 2018. He is also a member of the Corporate Governance Committee.

Mr. Scott served as Basilea's CEO from 2013 to 2018. Before that he held other key leadership positions at Basilea, including COO and from the Company’s founding in 2000 through January 2012 as CFO. From 2004 to 2011, Mr. Scott served on the Board of Directors and was also a co-founding Board member of the Company in 2000. Prior to joining Basilea, Mr. Scott worked at Roche Holding AG in management positions in finance, licensing and in the mergers & acquisitions group. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation in the United States as director in Prudential’s finance and international business development units, managing divestitures and joint venture transactions.

Mr. Scott is a member of the board of Medigene AG and of KIDpharma AG.

Mr. Scott holds a bachelor’s degree from Utah State University and a master’s degree from Harvard University.

Steven D. Skolsky, Member of the Board of Directors | Nationality: American | Year of Birth: 1956

Steven Skolsky has been a member of the Board of Directors since 2008. He is also a member of the Compensation Committee and of the Audit Committee.

Mr. Skolsky is principal at Expis Partners, a life science consultancy. He served as a senior executive at Quintiles Transnational Holdings from 2011 to 2016, most recently as senior vice president & managing director and formerly, head of global clinical operations. From 2006 to 2011, Mr. Skolsky served as the president & CEO of Sequoia Pharmaceuticals Inc. and from 2004 to 2006 as CEO of Trimeris Inc. Mr. Skolsky joined Trimeris from GlaxoSmithKline, where he had served for more than 20 years in a range of senior leadership roles, including senior vice president, global product strategy & clinical development, and managing director of GlaxoSmithKline’s operations in Australia and New Zealand.

Mr. Skolsky serves on the board of Clinipace Clinical Research and also on the foundation board of the Kenan-Flagler School of Business and the board of visitors at the University of North Carolina at Chapel Hill.

Mr. Skolsky holds a B.A. in biology from the University of North Carolina at Chapel Hill.

Board Committees

Audit Committee Compensation Committee Corporate Governance Committee
Mr. Domenico Scala 
(Chairman)
Dr. Martin Nicklasson
(Chairman)
Dr. Thomas Werner
(Chairman)
Dr. Martin Nicklasson Mr. Steven D. Skolsky Dr. Nicole Onetto
Mr. Steven D. Skolsky Dr. Thomas Werner Mr. Ronald Scott

For further information on the responsibilities of the Board committees, please refer to the latest annual report.

Management Committee

 

David Veitch, Chief Executive Officer | Nationality: British | Year of Birth: 1965

David Veitch has been Chief Executive Officer of Basilea since 2018.

Mr. Veitch joined Basilea in 2014 as Chief Commercial Officer. Before that, from 2012 to 2013, he served as the president of European operations at Savient Pharmaceuticals. From 2007 to 2011, he served as senior vice president of European marketing & brand commercialization at Bristol-Myers Squibb Pharmaceuticals. From 2004 to 2007, he was vice president & general manager UK at Bristol-Myers Squibb Pharmaceuticals. Prior to this Mr. Veitch held various general management and commercial roles in Bristol-Myers Squibb Pharmaceuticals and prior to that with SmithKline Beecham Pharmaceuticals.

Mr. Veitch holds a B.Sc. in Biology from the University of Bristol.

Marc Engelhardt, M.D., Chief Medical Officer | Nationality: German and American | Year of Birth: 1964

Marc Engelhardt, M.D., has been Chief Medical Officer of Basilea since 2018. He is a member of the Management Committee of Basilea.

Mr. Engelhardt previously held the position of Head of Development, leading Basilea’s clinical research and development group. He joined Basilea in 2010 as Head of Clinical Research. Before that, he served as global program medical director at Novartis Pharma AG and held various positions with increasing responsibility at Bracco-Altana, Germany and Bracco Diagnostics, USA.

Mr. Engelhardt holds a medical degree and a Ph.D. from the University Frankfurt/Main and is board certified in internal medicine.

Gerrit Hauck, Ph.D., Chief Technology Officer | Nationality: German | Year of Birth: 1964

Gerrit Hauck, Ph.D., has been Chief Technology Officer of Basilea since 2018. He is a member of the Management Committee of Basilea.

Mr. Hauck joined Basilea from Sanofi, where he held various technical operations and management functions during his 24-year career at Sanofi and its predecessor companies, including formulation development, plant management and global CMC leadership. Most recently he was cluster head synthetic molecules, overseeing most of Sanofi’s technical development programs for synthetic molecules from pre-clinical candidates to launch. Since January 2012 he was a member of Sanofi’s research stage gate committee, which was responsible for the transition of candidate molecules from research into development.

Mr. Hauck graduated as a pharmacist from the University of Heidelberg and holds a Ph.D. from Saarland University.

Adesh Kaul, Chief Financial Officer | Nationality: Swiss | Year of Birth: 1974

Adesh Kaul, has been Chief Financial Officer since April 2019. He is a member of the Management Committee of Basilea.

Mr. Kaul previously held the position of Chief Corporate Development Officer of Basilea since 2018 and before that Head of Corporate Development. He joined Basilea in 2009 as Head Business Development & Licensing, Investor Relations and as Head Public Relations & Corporate Communications. From 2015 to 2016, he held the position of CFO and head corporate development at Polyphor AG. From 2006 to 2009 Mr. Kaul was senior financial analyst at Neue Zürcher Bank and before that he held several senior executive positions in general management and in sales & marketing at Genedata AG.

Mr. Kaul holds master's degrees in Economics and in Biochemistry from the University of Basel, and an Executive MBA from the University of St. Gallen.

Laurenz Kellenberger, Ph.D., Chief Scientific Officer | Nationality: Swiss | Year of Birth: 1967

Laurenz Kellenberger, Ph.D., has been Chief Scientific Officer of Basilea since 2009. He is a member of the Management Committee of Basilea. Mr. Kellenberger joined Basilea in 2000 and held several leadership positions in research management with responsibilities for key projects from lead finding and optimization through to preclinical development, including as Head of Chemistry. He started his career as a researcher at the University of Cambridge and at F. Hoffmann-La Roche, where he held different positions in preclinical research and chemical technologies.

Mr. Kellenberger holds a Ph.D. in Organic Chemistry from the Swiss Federal Institute of Technology Zurich (ETH Zürich) and is author of numerous scientific publications.

Extended Management Committee

 

Ursula Eberhardt, Head of Global Human Resources | Nationality: Swiss | Year of Birth: 1962

Ursula Eberhardt has been Head of Global Human Resources of Basilea since 2017. She is a member of the Extended Management Committee of Basilea.

Mrs. Eberhardt joined Basilea in 2006 and held various leadership positions in Human Resources, including Deputy Head of Global Human Resources. Prior to joining Basilea, she worked in various marketing, communications and administration positions at Barclays Bank Ltd, Zurich and Dubach Advertising Agency.

Ms. Eberhardt holds a Swiss Federal Diploma in Marketing Communication and a Swiss Advanced Federal Diploma of Higher Education in Human Resources Management.

Damian Heller, General Counsel & Corporate Secretary | Nationality: Swiss | Year of Birth: 1966

Damian Heller has been General Counsel & Corporate Secretary of Basilea since 2017. He is a member of the Extended Management Committee of Basilea.

He joined Basilea in 2015 as Deputy General Counsel and Global Compliance Officer. Prior to joining Basilea, he worked for 20 years in the field of Legal, Compliance and Corporate Governance and held several leadership positions, including Director of the Basel Institute on Governance, Global Compliance Officer of Novartis Pharma AG and Corporate Secretary of Syngenta AG.

Mr. Heller holds a master’s degree in Law from the University of Basel and a master’s degree in Business Administration from the University of Rochester, New York.

Anne Stehlin, Ph.D., Head of Global Quality Management | Nationality: French | Year of Birth: 1976

Anne Stehlin, Ph.D., has been Head of Global Quality Management of Basilea since 2018. She is a member of the Extended Management Committee of Basilea.

Ms. Stehlin joined Basilea in 2018 as Deputy Head of Global Quality Management. Prior to joining Basilea, during her 13-year career at Novartis she held several positions with increasing responsibilities within Novartis Technical Operations, most recently as global head product quality lifecycle management at Novartis Pharma AG.

Ms. Stehlin is a certified pharmacist and holds a Ph.D. in Pharmaceutical Sciences from the University of Strasbourg.